Is the key to curing the world’s most challenging diseases hidden in unlocking the power of fragmented biological data?
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
Radiopharmaceuticals have also been the target of large partnership deals, including a recent $140 million partnership ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...
Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028 ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...